Ironwood Pharmaceuticals, Inc.  

(Public, NASDAQ:IRWD)   Watch this stock  
Find more results for IRWD
14.50
0.00 (0.00%)
Aug 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.18 - 14.63
52 week 12.48 - 19.94
Open 14.29
Vol / Avg. 1.29M/1.33M
Mkt cap 2.17B
P/E     -
Div/yield     -
EPS -0.97
Shares 135.03M
Beta 1.44
Inst. own 113%
Nov 1, 2017
Q3 2017 Ironwood Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Aug 3, 2017
Q2 2017 Ironwood Pharmaceuticals Inc Earnings Call - Webcast
Aug 2, 2017
Q2 2017 Ironwood Pharmaceuticals Inc Earnings Release
Jul 20, 2017
Ironwood Pharmaceuticals Inc to Discuss the Top-Line Results of the IW-3718 Phase Conference Call
Jun 15, 2017
Ironwood Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference - Webcast
Jun 8, 2017
Ironwood Pharmaceuticals Inc at Jefferies Healthcare Conference
May 31, 2017
Ironwood Pharmaceuticals Inc Annual Shareholders Meeting - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -67.96% -29.83%
Operating margin -63.02% -18.93%
EBITD margin - -14.68%
Return on average assets -25.23% -12.30%
Return on average equity -1028.09% -100.97%
Employees 674 -
CDP Score - -

Address

301 Binney St
CAMBRIDGE, MA 02142-1030
United States - Map
+1-617-6217722 (Phone)
+1-617-4940480 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

Officers and directors

Peter M. Hecht Ph.D. Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Thomas Graney Chief Financial Officer, Senior Vice President - Finance, Corporate Strategy
Age: 52
Bio & Compensation  - Reuters
Mark G. Currie Ph.D. Senior Vice President, Chief Scientific Officer, President - Research and Development
Age: 62
Bio & Compensation  - Reuters
Thomas A. McCourt Senior Vice President - Marketing and Sales, Chief Commercial Officer
Age: 59
Bio & Compensation  - Reuters
Halley E. Gilbert Esq. Senior Vice President, Chief Legal Officer, Secretary
Age: 47
Bio & Compensation  - Reuters
Christopher I. Wright M.D. Ph.D. Senior Vice President - Global Development and Chief Development Officer
Bio & Compensation  - Reuters
Terrance G. McGuire Non-Executive Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Andrew Dreyfus Independent Director
Age: 58
Bio & Compensation  - Reuters
Marsha H. Fanucci Independent Director
Age: 63
Bio & Compensation  - Reuters
Julie H. McHugh Independent Director
Age: 52
Bio & Compensation  - Reuters